UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Carboplatin in the neoadjuvant treatment of triple-negative breast cancer—ready for prime time?

Annals of oncology, 2018-12, Vol.29 (12), p.2278-2280

Foukakis, T.

2018

Volltextzugriff (PDF)

SOLAR1s: alpelisib returns to earth?

Annals of oncology, 2021-02, Vol.32 (2), p.129-132

2021

Volltextzugriff (PDF)

Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?

Annals of oncology, 2019-07, Vol.30 (7), p.1044-1050

2019

Volltextzugriff (PDF)

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

Annals of oncology, 2020-05, Vol.31 (5), p.569-581

2020

Volltextzugriff (PDF)

Adjuvant abemaciclib for high-risk breast cancer: the story continues

Annals of oncology, 2021-12, Vol.32 (12), p.1457-1459

2021

Volltextzugriff (PDF)

The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer

Journal of internal medicine, 2015-12, Vol.278 (6), p.545-570

2015

Volltextzugriff (PDF)

Minimally invasive tissue access as a tool for delivering personalized medicine – with focus on oncology

Journal of internal medicine, 2019-04, Vol.285 (4), p.395-397

2019

Volltextzugriff (PDF)

Axillary evaluation in ductal cancer in situ of the breast: challenging the diagnostic accuracy of clinical practice guidelines

British journal of surgery, 2021, Vol.108 (9), p.1120-1125

2021

Volltextzugriff (PDF)

Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics

British journal of cancer, 2014-03, Vol.110 (5), p.1378-1384

2014

Volltextzugriff (PDF)

The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis

ESMO open, 2021-12, Vol.6 (6), p.100289, Article 100289

2021

Volltextzugriff (PDF)

A multimodal approach for the management of co-morbid cardiotoxicity in the elderly breast cancer patients

EUROPEAN JOURNAL OF CANCER, 2022, Vol.175, p.S40

2022

Volltextzugriff (PDF)

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients

Annals of oncology, 2019-01, Vol.30 (1), p.109-114

2019

Volltextzugriff (PDF)

When to order a biopsy to characterise a metastatic relapse in breast cancer

Annals of oncology, 2012-09, Vol.23 Suppl 10, p.x349-x353

2012

Volltextzugriff (PDF)

P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study

Breast (Edinburgh), 2023-04, Vol.68, p.S63-S64

2023

Volltextzugriff (PDF)

Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study

Cancers, 2022, Vol.14 (11), p.2615

2022

Volltextzugriff (PDF)

Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy

ANNALS OF ONCOLOGY, 2019, Vol.30, p.v86-v87

2019

Volltextzugriff (PDF)

PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels

ANNALS OF ONCOLOGY, 2020, Vol.31 (Suppl. 2), p.S49

2020

Volltextzugriff (PDF)

Prognosis after loco-regional recurrence of breast cancer: 35 years longitudinal data from the Stockholm cancer register

ANNALS OF ONCOLOGY, 2017-09, Vol.28, p.v95-v95

2017

Volltextzugriff (PDF)

Sixteen months follow-up of health related quality of life in women with high-risk breast cancer after random assignment to adjuvant treatment with tailored dose-dense chemotherapy vs standard three-weekly adjuvant chemotherapy (PANTHER study)

EUROPEAN JOURNAL OF CANCER, 2017, Vol.72, p.S3-S3

2017

Volltextzugriff (PDF)

Ribociclib in premenopausal women with advanced breast cancer

The lancet oncology, 2018-07, Vol.19 (7), p.850-852

Foukakis, Theodoros

2018

Volltextzugriff (PDF)

An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors

Clinical cancer research, 2016-05, Vol.22 (10), p.2417-2426

2016

Volltextzugriff (PDF)

CTCA toxicity scoring and EORTC quality of life questionnaire: A comparison of physicians’ and patients’ scoring of toxicity in the “Panther trial”

ANNALS OF ONCOLOGY, 2017, Vol.28, p.v507

2017

Volltextzugriff (PDF)

Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer

ANNALS OF ONCOLOGY, 2017, Vol.28 (Suppl. 5), p.v68-v68

2017

Volltextzugriff (PDF)

Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)

ESMO open, 2021-08, Vol.6 (4), p.100217-100217, Article 100217

2021

Volltextzugriff (PDF)

Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing

Cell, 2018-05, Vol.173 (4), p.879-893.e13

2018

Volltextzugriff (PDF)

1 – 25 von 264

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(254)
Mit Volltextzugriff
(242)

Publikationsform

Sprache

Englisch
(264)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(32)
Cancer Research
(23)
Esmo Open
(15)
Journal Of Clinical Oncology
(13)
Breast Cancer Research And Treatment
(10)
The New England Journal Of Medicine
(7)
Acta Oncologica
(5)
British Journal Of Cancer
(5)
Cancers
(5)
Clinical Cancer Research
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Carboplatin in the neoadjuvant treatment of triple-negative breast cancer—ready for prime time?

SOLAR1s: alpelisib returns to earth?

Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

Adjuvant abemaciclib for high-risk breast cancer: the story continues

The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer

Minimally invasive tissue access as a tool for delivering personalized medicine – with focus on oncology

Axillary evaluation in ductal cancer in situ of the breast: challenging the diagnostic accuracy of clinical practice guidelines

Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics

The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis

A multimodal approach for the management of co-morbid cardiotoxicity in the elderly breast cancer patients

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients

When to order a biopsy to characterise a metastatic relapse in breast cancer

P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study

Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study

Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy

PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels

Prognosis after loco-regional recurrence of breast cancer: 35 years longitudinal data from the Stockholm cancer register

Sixteen months follow-up of health related quality of life in women with high-risk breast cancer after random assignment to adjuvant treatment with tailored dose-dense chemotherapy vs standard three-weekly adjuvant chemotherapy (PANTHER study)

Ribociclib in premenopausal women with advanced breast cancer

An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors

CTCA toxicity scoring and EORTC quality of life questionnaire: A comparison of physicians’ and patients’ scoring of toxicity in the “Panther trial”

Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer

Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)

Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing

Suchergebnisse filtern